February 21, 2025

New Blood-Based Screening Test Accurately Detects Colorectal Cancer Risk in Adults Aged 45 and Older

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease.1

The ASCO Post

February 21, 2025

Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup

An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastroin...

The ASCO Post

February 20, 2025

Adding Tumor Deposit Status to Cancer Staging May Improve Prognostication in Colorectal Cancer

Investigators assessed whether adding tumor deposit status to colorectal cancer staging may enhance prognostication.

The ASCO Post

February 18, 2025

Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk?

Evaluation of the clinical performance of an investigational blood-based colorectal cancer screening test showed the tool accurately detected colorectal cancer risk in adults aged 45 years and older w...

The ASCO Post

February 14, 2025

Potential Benefit of Consuming Yogurt in Decreasing the Risk of Certain Types of Colorectal Cancers

Investigators have explored whether long-term yogurt intake may protect against the development of colorectal cancer through changes in the gut microbiome.

The ASCO Post

February 13, 2025

Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E...

The ASCO Post

February 11, 2025

Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup

An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastroin...

The ASCO Post

January 27, 2025

Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer

First-line treatment with dual-targeted therapies plus a modified chemotherapy regimen may be effective in patients with BRAF V600E–mutated metastatic colorectal cancer, according to recent findings p...

The ASCO Post

February 15, 2024

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Circulating tumor DNA may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from receiving adjuvant chemotherapy. The re...

The ASCO Post